| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 17/06/2024 | 13:02 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 16/06/2024 | 11:30 | GlobeNewswire Inc. | Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 14/06/2024 | 00:39 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 11/06/2024 | 22:06 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 10/06/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024) | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 03/06/2024 | 22:58 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 29/05/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 28/05/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 20/05/2024 | 22:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Board Chair Transition | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 14/05/2024 | 16:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024) | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 07/05/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 17/04/2024 | 00:21 | GlobeNewswire Inc. | Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 12/04/2024 | 05:38 | GlobeNewswire Inc. | Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 11/04/2024 | 22:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Proposed Public Offering | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 10/04/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 09/04/2024 | 19:15 | GlobeNewswire Inc. | Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 09/04/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 03/04/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics to Participate in Upcoming Investor Conferences | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 02/04/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 25/03/2024 | 12:00 | GlobeNewswire Inc. | Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 20/03/2024 | 14:40 | GlobeNewswire Inc. | Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 11/03/2024 | 12:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 05/03/2024 | 22:30 | GlobeNewswire Inc. | Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 15/02/2024 | 22:51 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 15/02/2024 | 22:00 | GlobeNewswire Inc. | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 14/02/2024 | 14:51 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 01/02/2024 | 22:01 | GlobeNewswire Inc. | Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 29/01/2024 | 22:00 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 16/01/2024 | 22:48 | Dow Jones News | Nurix Therapeutics Gets FDA Fast-Track Designation for NX-5948 | NASDAQ:NRIX | Nurix Therapeutics Inc |
| 16/01/2024 | 22:01 | GlobeNewswire Inc. | Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL | NASDAQ:NRIX | Nurix Therapeutics Inc |